2. Search Result
Search Result
Results for "

WDR5

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-154949
    WDR5-IN-6

    		WDR5 Cancer
    WDR5-IN-6 is a WDR5 inhibitor, targeting to WBM site. WDR5-IN-6 inhibits cell proliferation of neuroblastoma cell lines with potent anti-tumor activity. WDR5-IN-6 shows high synergy with OICR-9429 (HY-16993), a WDR5 inhibitor targeting to WIN site. WDR5-IN-6 can be used for reasearch in neuroblastoma .
    <em>WDR5</em>-IN-6
  • HY-162014
    WDR5 degrader-1

    		PROTACs Cancer
    WDR5 degrader-1 (compound 25) is a cereblon (CRBN)-recruiting WDR5 degrader. WDR5 degrader-1 selectively degraded WDR5 over the CRBN neo-substrate IKZF1 .
    <em>WDR5</em> degrader-1
  • HY-RS15785
    WDR5 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    WDR5 Human Pre-designed siRNA Set A contains three designed siRNAs for WDR5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    WDR5 Human Pre-designed siRNA Set A
    WDR5 Human Pre-designed siRNA Set A
  • HY-161123
    WDR5-IN-8

    		WDR5 Cancer
    WDR5-IN-8 is a WDR5 inhibitor with IC50 value of 15.5 nM. WDR5-IN-8 shows good anti-proliferative activity in two human acute leukemia cell lines. WDR5-IN-8 has antitumor activity .
    <em>WDR5</em>-IN-8
  • HY-157332
    WDR5-IN-7

    		Histone Methyltransferase Cancer
    WDR5-IN-7 (Compound 22) is an orally bioavailable benzoxazepinone-based WD repeat domain 5 (WDR5) inhibitor. WDR5-IN-7 can be used for the research of anti-cancer .
    <em>WDR5</em>-IN-7
  • HY-150654
    WDR5-IN-5

    		Histone Methyltransferase Cancer
    WDR5-IN-5 is an orally active and selective inhibitor of WIN site of WD repeat domain 5 (WDR5). WDR5-IN-5 exhibits anti-proliferative activity towards cancer cells and good pharmacokinetics profile in mice. WDR5-IN-5 shows high affinity to WDR5 and the binding affinity Ki value <0.02 nM .
    <em>WDR5</em>-IN-<em>5</em>
  • HY-133121
    WDR5-IN-1

    		Histone Methyltransferase Apoptosis Cancer
    WDR5-IN-1 is a potent and selective WD repeat domain 5 (WDR5) inhibitor, with a Kd of <0.02 nM. WDR5-IN-1 inhibits MLL1 histone methyltransferase (HMT) activity with an IC50 of 2.2 nM. WDR5-IN-1 diminishes MYC recruitment at WDR5-displaced genes and exhibits potent anti-proliferative effects in CHP-134 (neuroblastoma) and Ramos (Burkitt’s lymphoma) lines .
    <em>WDR5</em>-IN-1
  • HY-111753
    WDR5-IN-4

    		Histone Methyltransferase Cancer
    WDR5-IN-4 is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. WDR5-IN-4 displaces WDR5 from chromatin and decreases the expression of associated genes, causing translational inhibition, nucleolar stress. Anti-cancer activity .
    <em>WDR5</em>-IN-4
  • HY-111753A
    WDR5-IN-4 TFA
    3 Publications Verification

    		 Histone Methyltransferase Cancer
    WDR5-IN-4 TFA is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. WDR5-IN-4 TFA displaces WDR5 from chromatin and decreases the expression of associated genes, causing translational inhibition, nucleolar stress. Anti-cancer activity .
    <em>WDR5</em>-IN-4 TFA
  • HY-19347
    WDR5-0103

    WD-Repeat Protein 5-0103

    		 Histone Methyltransferase Cancer
    WDR5-0103 is a potent and selective WD repeat-containing protein 5 (WDR5) antagonist with Kd of 450 nM.
    <em>WDR5</em>-0103
  • HY-148817
    WDR5-0102

    		WDR5 Cancer
    WDR5-0102 is an inhibitor targeting WDR5-MLL1 interface (Kdis=7 μM, Kd=4 μM). WDR5-0102 suppresses MLL1 HMT activity, but not human H3K4 methyltransferase SETD7 and six other HMTs: G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5 .
    <em>WDR5</em>-0102
  • HY-RS15789
    WDR5B Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    WDR5B Human Pre-designed siRNA Set A contains three designed siRNAs for WDR5B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    WDR5B Human Pre-designed siRNA Set A
    WDR5B Human Pre-designed siRNA Set A
  • HY-141797
    MS33

    		Histone Methyltransferase PROTACs Cancer
    MS33 is a potent WDR5 degrader, with Kds of 870 nM and 120 nM for VCB and WDR5, respectively. MS33 induces WDR5 degradation in an E3 ligase VHL, and proteasome-dependent manner. MS33 can be used for the research of acute myeloid leukemia .
    MS33
  • HY-16994
    OICR-0547

    		WDR5 Cancer
    OICR-0547 is a negative control, closely related derivative of OICR-9429 (HY-16993). OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction. OICR-0547 is an inactive control compound that no longer binds to WDR5 .
    OICR-0547
  • HY-150403
    XF067-68

    		PROTACs Histone Methyltransferase Cancer
    XF067-68 is a PROTAC for targeted degradation of WD40 repeat domain protein 5 (WDR5) (extracted from patent WO2019246570A1) .
    XF067-68
  • HY-153728
    WM-586

    		Histone Methyltransferase Cancer
    WM-586 is a covalent WDR5 inhibitor that disrupts the binding of WDR5 to MYC. WM-586 specifically decreases cellular WDR5 and MYC interaction with the IC50 of 101 nM in HTRF assay .
    WM-586
  • HY-100869B
    MM-589 (racemic mixture ) (TFA)

    		Histone Methyltransferase Cancer
    MM-589 (racemic mixture) TFA, is a racemic mixture of MM-589 TFA (HY-100869A). MM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM .
    MM-589 (racemic mixture ) (TFA)
  • HY-150400
    XF056-132 free base

    		PROTACs Histone Methyltransferase Cancer
    XF056-132 free base is a potent WDR5 (WD40 repeat domain protein 5) PROTAC degrader .
    XF056-132 free base
  • HY-149873
    Anticancer agent 126

    		Histone Methyltransferase Cancer
    Anticancer agent 126 (compound 12) is a WDR5 inhibitor with anticancer effects. Anticancer agent 126 disrupts WDR5-MYC interaction in cells and reduce MYC target gene expression .
    Anticancer agent 126
  • HY-12220
    MM-102
    4 Publications Verification

    HMTase Inhibitor IX

    		 Histone Methyltransferase Cancer
    MM-102 (HMTase Inhibitor IX) is a potent WDR5/MLL interaction inhibitor, achieves IC50= 2.4 nM with an estimated Ki< 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide.
    MM-102
  • HY-132233
    DDO-2093

    		Histone Methyltransferase Cancer
    DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex .
    DDO-2093
  • HY-132233A
    DDO-2093 dihydrochloride

    		Histone Methyltransferase Cancer
    DDO-2093 dihydrochloride is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 dihydrochloride selectively inhibits the catalytic activity of MLL complex .
    DDO-2093 dihydrochloride
  • HY-12220A
    MM-102 TFA
    4 Publications Verification

    HMTase Inhibitor IX TFA

    		 Histone Methyltransferase Cancer
    MM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide.
    MM-102 TFA
  • HY-141799
    Dimethyl-F-OICR-9429-COOH

    		Ligands for Target Protein for PROTAC Cancer
    Dimethyl-F-OICR-9429-COOH a ligand for WD40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1 intermediate 19. Dimethyl-F-OICR-9429-COOH can be used in the synthesis of PROTACs .
    Dimethyl-F-OICR-9429-COOH
  • HY-16993
    OICR-9429
    Maximum Cited Publications
    7 Publications Verification

    		 Histone Methyltransferase Apoptosis Cancer
    OICR-9429 is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .
    OICR-9429
  • HY-141796
    MS67

    		Histone Methyltransferase PROTACs Cancer
    MS67 is a potent and selective WD40 repeat domain protein 5 (WDR5) degrader with a Kd of 63 nM. MS67 is inactive against other protein methyltransferases, kinases, GPCRs, ion channels, and transporters. MS67 shows potent acticancer effects .
    MS67
  • HY-153331
    DDO-2213

    		WDR5 Cancer
    DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research .
    DDO-2213
  • HY-100869
    MM-589

    MM-589 is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM .
    MM-589
  • HY-100869A
    MM-589 TFA

    		Histone Methyltransferase Cancer
    MM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM .
    MM-589 TFA
  • HY-154847
    WM-662

    		Histone Methyltransferase Neurological Disease Metabolic Disease Cancer
    WM-662 is a WDR5-MYC interaction inhibitor, with an IC50 of 18 μM. WM-662 has potential for the research of cancer, aging, and neurodegenerative disorders .
    WM-662
  • HY-141798
    OICR-9429-N-C2-NH2

    		Ligands for Target Protein for PROTAC Cancer
    OICR-9429-N-C2-NH2 is a ligand for Wd40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1, intermediate 2. OICR-9429-N-C2-NH2 can be used in the synthesis of PROTACs .
    OICR-9429-N-C2-NH2
  • HY-19554
    MM-401

    MM-401 is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC50 = 0.32 µM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia .
    MM-401
  • HY-19554A
    MM-401 TFA
    1 Publications Verification

    		 Histone Methyltransferase Apoptosis Cancer
    MM-401 (TFA) is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC50 = 0.32 µM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia .
    MM-401 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: